Evenamide is a new medication being studied as an add-on treatment for patients with treatment-resistant schizophrenia. It works alongside existing antipsychotic medications when the current treatment alone is not providing adequate control of schizophrenia symptoms. This medication is being tested to see if it can help improve the symptoms of schizophrenia when other treatments haven’t worked well enough.

Antipsychotic medications (current patient medications) are medicines that patients in the trial will continue taking at their usual stable dose. These are the existing medications that patients were already using to manage their schizophrenia symptoms before joining the study.

Treatment-resistant schizophrenia – A severe form of schizophrenia where symptoms persist despite adequate treatment with standard antipsychotic medications. This condition is characterized by ongoing hallucinations, delusions, and disorganized thinking that continue even when patients take their prescribed medications as directed. Patients with this form of schizophrenia experience persistent positive symptoms (such as hearing voices or having false beliefs) and negative symptoms (such as reduced emotional expression or lack of motivation). The condition typically develops after a person has shown insufficient response to at least two different antipsychotic medications taken at appropriate doses for an adequate duration.